GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 17, 2025.

via HealthDay

WEDNESDAY, Sept. 17, 2025 -- Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with knee osteoarthritis (OA) and obesity, according to a study published online Sept. 16 in Annals of Internal Medicine.

Daniel J. Betensky, from Brigham and Women's Hospital in Boston, and colleagues examined the cost-effectiveness of semaglutide and tirzepatide for patients with knee osteoarthritis and obesity. The base-case cohort included patients with a Western Ontario and McMaster Universities Osteoarthritis Index pain score of 71 and mean body mass index (BMI) of 40 kg/m2.

The researchers found that in the base-case analysis, tirzepatide provided greater health benefits at lower costs than semaglutide, and compared with diet and exercise, tirzepatide yielded a $57,400 per quality-adjusted life year (QALY) incremental cost-effectiveness ratio (ICER). Compared with the two GLP-1 RAs, for those eligible, Roux-en-Y gastric bypass (RYGB) provided greater health benefits at lower costs and had a $30,700 per QALY ICER compared with laparoscopic sleeve gastrectomy. Tirzepatide's ICER was most sensitive to changes in medication costs, treatment efficacy, and baseline BMI in the sensitivity analysis. The probability of being cost-effective at a $100,000 per QALY threshold was 64 percent for tirzepatide and 34 percent for semaglutide.

"Clinicians may consider discussing the differences between these weight loss interventions, their potential benefits and harms, and currently available knee osteoarthritis care options with their eligible patients," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-09-18 16:18

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords